Melanocortins protect against brain damage and counteract cognitive decline in a transgenic mouse model of moderate Alzheimer׳s disease.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Pharmacology

• Publication date

  2014-10-05

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.ejphar.2014.06.063PMID 25034807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways.

  2014influential reference
• Immunotherapy against amyloid pathology in Alzheimer's disease.

  2013influential reference
• Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

  2013cited by this paper
• Human LilrB2 Is a β-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer’s Model

  2013cited by this paper
• Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms.

  2013cited by this paper
• Zif268/egr1 gene controls the selection, maturation and functional integration of adult hippocampal newborn neurons by learning

  2013cited by this paper
• Up-regulation of the canonical Wnt-3A and Sonic hedgehog signaling underlies melanocortin-induced neurogenesis after cerebral ischemia.

  2013cited by this paper
• Melanocortin-4 Receptor Regulates Hippocampal Synaptic Plasticity through a Protein Kinase A-Dependent Mechanism

  2013cited by this paper
• Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid-β Levels

  2013cited by this paper
• Preclinical Alzheimer disease—the challenges ahead

  2013cited by this paper
• Cell and Gene Therapy in Alzheimer's Disease

  2013cited by this paper
• Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury*

  2012influential reference
• Melanocortin 4 receptor activation induces brain-derived neurotrophic factor expression in rat astrocytes through cyclic AMP-protein kinase A pathway.

  2012cited by this paper
• Melanocortins as potential therapeutic agents in severe hypoxic conditions.

  2012influential reference
• Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.

  2012cited by this paper
• Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice

  2012cited by this paper
• Protective action of NDP-MSH in experimental subarachnoid hemorrhage.

  2012cited by this paper
• Systems neuroscience: The stress of dieting

  2011cited by this paper
• α-MSH: A Potential Neuroprotective and Immunomodulatory Agent for the Treatment of Stroke

  2011cited by this paper
• Opportunities and challenges in developing Alzheimer disease therapeutics

  2011cited by this paper
• Melanocortin MC₄ receptor agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia.

  2011cited by this paper
• Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

  2011cited by this paper
• Potential therapeutic uses of BDNF in neurological and psychiatric disorders

  2011cited by this paper
• Treatment of cerebral ischemia with melanocortins acting at MC4 receptors induces marked neurogenesis and long-lasting functional recovery

  2011cited by this paper
• Targeting the melanocortin receptor system for anti-stroke therapy.

  2011cited by this paper
• Melanocortin 4 receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway*

  2011cited by this paper
• Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions

  2011cited by this paper
• Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study

  2011cited by this paper
• Effect of alpha-melanocyte stimulating hormone on locomotor recovery following spinal cord injury in mice: Role of serotonergic system.

  2011cited by this paper
• Cost of disorders of the brain in Europe 2010.

  2011cited by this paper
• Biomarkers in Alzheimer's disease drug development

  2010influential reference
• Alzheimer's disease, a multifactorial disorder seeking multitherapies

  2010cited by this paper
• Degeneration and repair in central nervous system disease

  2010cited by this paper
• Distribution and function of melanocortin receptors within the brain.

  2010cited by this paper
• Science of self-preservation: how melanocortin action in the brain modulates body weight, blood pressure, and ischemic damage.

  2009cited by this paper
• Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268.

  2009cited by this paper
• Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic.

  2009cited by this paper
• Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction

  2008influential reference
• Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies.

  2008cited by this paper
• Reduction of ischemic stroke in rat brain by alpha melanocyte stimulating hormone.

  2008cited by this paper
• Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.

  2008cited by this paper
• Experience-Specific Functional Modification of the Dentate Gyrus through Adult Neurogenesis: A Critical Period during an Immature Stage

  2007cited by this paper
• Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins.

  2007cited by this paper
• Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease

  2007cited by this paper
• Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage

  2007cited by this paper
• Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia.

  2006cited by this paper
• [d-Trp8]-γ-Melanocyte-Stimulating Hormone Exhibits Anti-Inflammatory Efficacy in Mice Bearing a Nonfunctional MC1R (Recessive Yellow e/e Mouse)

  2006cited by this paper
• Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation

  2004influential reference
• Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

  2003cited by this paper
• VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia.

  2003cited by this paper
• Further evidence that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC3 receptors.

  2003cited by this paper
• Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats.

  2002cited by this paper
• Protective effect of melanocortin peptides in rat myocardial ischemia.

  2001cited by this paper
• The physiological role of melanocortin receptors.

  2001cited by this paper
• Role of melanocortins in the central control of feeding.

  2000cited by this paper
• Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo.

  1998influential reference
• Egr transcription factors in the nervous system.

  1997cited by this paper
• Effect of dystrophin antisense oligonucleotides on cultured human neurons.

  1997cited by this paper
• Adrenocorticotropin normalizes the blood levels of nitric oxide in hemorrhage-shocked rats.

  1997cited by this paper
• Influence of ACTH‐(1–24) on free radical levels in the blood of haemorrhage‐shocked rats: direct ex vivo detection by electron spin resonance spectrometry

  1996cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• The adrenocorticotropic hormone (ACTH)-induced reversal of hemorrhagic shock.

  1989cited by this paper
• CSF α‐MSH in dementia of the Alzheimer type

  1988cited by this paper
• CSF alpha-MSH in dementia of the Alzheimer type.

  1988cited by this paper
• Extrahypophyseal distribution of α-melanocyte stimulating hormone (α-MSH)-like immunoreactivity in postmortem brains from normal subjects and Alzheimer-type dementia patients

  1986cited by this paper
• Is alpha-MSH deficiency the cause of Alzheimer's disease?

  1986cited by this paper
• Extrahypophyseal distribution of alpha-melanocyte stimulating hormone (alpha-MSH)-like immunoreactivity in postmortem brains from normal subjects and Alzheimer-type dementia patients.

  1986cited by this paper
• Central ACTH deficit in degenerative and vascular dementia.

  1984cited by this paper

• Metabolic and Immune System Dysregulation: Unraveling the Connections between Alzheimer’s Disease, Diabetes, Inflammatory Bowel Diseases, and Rheumatoid Arthritis

  2024cites this paper
• Anorexigenic neuropeptides as anti-obesity and neuroprotective agents: exploring the neuroprotective effects of anorexigenic neuropeptides

  2024cites this paper
• The melanocortin receptor signaling system and its role in neuroprotection against neurodegeneration: Therapeutic insights

  2023cites this paper
• Transcriptomic Analyses of Neurotoxic Astrocytes Derived from Adult Triple Transgenic Alzheimer’s Disease Mice

  2023cites this paper
• Editorial: Melanocortins and melanocortin receptors in the regulation of inflammation: mechanisms and novel therapeutic strategies

  2023cites this paper
• A gel-forming α-MSH analog promotes lasting melanogenesis.

  2023cites this paper
• Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance

  2023cites this paper
• Melanocortin receptor agonist NDP-α-MSH improves cognitive deficits and microgliosis but not amyloidosis in advanced stages of AD progression in 5XFAD and 3xTg mice

  2023cites this paper
• Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer’s Disease Brain

  2022cites this paper
• Melanocortin receptor activation alleviates amyloid pathology and glial reactivity in an Alzheimer’s disease transgenic mouse model

  2021cites this paper
• Clustering-based time series analysis on insulin response in the blood-brain barrier

  2021cites this paper
• Aged Brains Express Less Melanocortin Receptors, Which Correlates with Age-Related Decline of Cognitive Functions

  2021cites this paper
• Roles of taurine in cognitive function of physiology, pathologies and toxication.

  2019cites this paper
• The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology.

  2019cites this paper
• NDP‐MSH reduces oxidative damage induced by palmitic acid in primary astrocytes

  2019cites this paper
• Small Molecule Neuropeptide S and Melanocortin 4 Receptor Ligands as Potential Treatments for Substance Use Disorders.

  2019cites this paper
• α-Melanocyte-Stimulating Hormone Attenuates Neovascularization by Inducing Nitric Oxide Deficiency via MC-Rs/PKA/NF-κB Signaling

  2018cites this paper
• Α-Melanocyte-Stimulating Hormone Protects Early Diabetic Retina from Blood-Retinal Barrier Breakdown and Vascular Leakage via MC4R

  2018cites this paper
• A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.

  2017cites this paper
• Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice.

  2017cites this paper
• Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives

  2017influential citation
• The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.

  2016cites this paper
• An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

  2016cites this paper
• Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease

  2016cites this paper
• The Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids

  2016cites this paper
• Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases

  2015cites this paper
• α-Melanocyte-stimulating hormone prevents glutamate excitotoxicity in developing chicken retina via MC4R-mediated down-regulation of microRNA-194

  2015cites this paper
• NDP-α-MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melanocortin MC4 receptors.

  2015influential citation
• Stimulation of the melanocortin-1 receptor leads to direct neuroprotection via orphan nuclear 4 receptor in inflammatory neurodegeneration

  year unknowncites this paper